DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20214048

Role of Topical Corticosteroid Therapy in Various Dermatoses

Jitendra Kishore Singh, Yogesh Rupram Zanwar, Jagannath Kumar, Jatin Jayeshbhai Patel, Vineet Chandrabhushan Dube, Madhurendra Kumar Sinha, Tanushree Biswas, Ramchander Dharak, Pankaj Tiwary, Priyanka Kartik Sutariya

Abstract


Topical corticosteroids are the cornerstone in managing several dermatologic disorders, including plaque psoriasis.Managing plaque psoriasis warrants the use of an effective anti-inflammatory, antimitotic, antipruritic, and immunosuppressive agent, such as clobetasol propionate (CP). Recently, CP 0.025% cream received approval by United States food and drug administration (US FDA) for the treatment of moderate-to-severe psoriasis in adult patients. CP 0.025% cream has proven efficacious in chronic skin diseases, including controlling inflammation and pruritus, in various steroid-responsive dermatoses. In contrast to prior CP formulations, this novel CP 0.025% cream formulation does not contain propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, which are known contact allergens. The other beneficial attributes of this CP 0.025% cream formulation are high penetration of active ingredients and a lower degree of systemic absorption. This case series discusses the experience of using CP 0.025% cream in terms of its efficacy and safety in various dermatologic conditions. 


Keywords


Plaque psoriasis, CP 0.025%, Topical corticosteroid

Full Text:

PDF

References


Del Rosso JQ. Topical corticosteroid therapy for psoriasis-a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Zampetti A, Feliciani C, Tulli A, Amerio P. Pharmacotherapy of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses focus on clobetasol propionate. Clin Med Insights Ther. 2010;2:523-37.

Draelos ZD, Fowler JF, Cornelison R. A Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with Clobetasol Propionate Cream (Impoyz™), 0.025% versus Clobetasol Propionate (Temovate®). J Cutan Med Surg. 2018;2(6):410-20.

Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;3:CD005028.

Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg. 2003;7(3):185-92.

Prescribing information. Impoyz (clobetasol propionate) Cream, 0.025%, for topical use. Available at: https://www.accessdata.fda.gov/ drugsatfda_docs/label/2017/209483s000lbl.pdf. Accessed on 8 July 2021.

Usatine RP, Riojas M. Diagnosis and management of contact dermatitis. Am Fam Physician. 2010;82(3):249-55.

Das A, Panda S. Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach. Indian J Dermatol. 2017;62(3):237-50.